Genitourinary Cancer

No Decrease in Pulmonary, Surgical Outcomes With Bleomycin in Good-Risk Germ Cell Cancers

No Decrease in Pulmonary, Surgical Outcomes With Bleomycin in Good-Risk Germ Cell Cancers

By

Researchers investigated whether bleomycin posed concerns regarding pulmonary or operative outcomes following PC-RPLND in men treated with chemotherapy for IGCCCG good-risk germ cell cancers.

Nonopioid Pain Medications Found to Control Postop Pain, Reduce Anxiety Effectively

Nonopioid Pain Medications Found to Control Postop Pain, Reduce Anxiety Effectively

By

Researchers presented results of a project designed to reduce opioid use while effectively managing pain and anxiety in patients who had undergone surgery for urologic cancer at the 2018 ASCO Quality Care Symposium.

Metformin Use May Improve Survival Outcomes in Bladder Cancer

Metformin Use May Improve Survival Outcomes in Bladder Cancer

By

A review and meta-analysis evaluated the association between metformin use and bladder cancer incidence and various prognostic measures, such as PFS and OS.

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

By

Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.

Postresection intravesical instillation of gemcitabine decreases non-muscle-invasive urothelial cancer recurrence

1. In this randomized controlled trial, time to recurrence was lower in patient with non-muscle-invasive urothelial cancer when treated with intravesical gemcitabine as compared to saline controls. 2. There was no difference in all-cause mortality between the two treatment groups. Evidence Rating: 1 (Excellent) Study Rundown: Non-muscle-invasive urothelial cancer is the most common form of []

5-ARI Use Before, After Diagnosis Significantly Reduced Bladder Cancer-Specific Death 

5-ARI Use Before, After Diagnosis Significantly Reduced Bladder Cancer-Specific Death 

By

Study results support the role of androgens and benefits of 5-alpha-reductase inhibition in the progression of bladder cancer.

Recruitment for 2 Trials of Investigational ADC for Urothelial Cancer Underway

Recruitment for 2 Trials of Investigational ADC for Urothelial Cancer Underway

By

Enfortumab vedotin was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA), based on interim results from a Phase 1 study.

Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors

Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors

By

Recent research shows that although testicular cancer survivors do not totally conform to the criteria for metabolic syndrome, past treatment with platinum-based chemotherapy increases its prevalence among survivors and may lead to a greater risk for heart disease in this patient population.

Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer

Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer

By

Results from the ongoing Platinum Study revealed the prevalence of risk factors for CVD among survivors of testicular cancer who received chemotherapy for their cancer.

Hemodialysis Indicative of Higher Mortality After Bladder Cancer Surgery

Hemodialysis Indicative of Higher Mortality After Bladder Cancer Surgery

By

Patients on hemodialysis that underwent radical cystectomy for bladder cancer experienced increased mortality.

Liquid Biopsy Results Could Guide, Expedite Clinical Trial Enrollment 

Liquid Biopsy Results Could Guide, Expedite Clinical Trial Enrollment 

By

Researchers assessed the use of cfDNA-based liquid biopsy to guide and expedite clinical trial enrollment for patients with with metastatic urothelial carcinoma.

Delirium Screening Tool Found Effective for Nurse Assessment of Delirium in Surgical Patients

Delirium Screening Tool Found Effective for Nurse Assessment of Delirium in Surgical Patients

By

After assessing and addressing nurse knowledge of use of the Confusion Assessment Method (CAM) tool, implementation of screening protocol improved interventions for older hospitalized patients who had undergone urological surgery. These results were presented in a poster at the NACNS 2018 Annual Conference.

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

By

Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.

Adjuvant Gemcitabine Regimen Improves PFS in Upper Tract Urothelial Cancer

Adjuvant Gemcitabine Regimen Improves PFS in Upper Tract Urothelial Cancer

By

Investigators compared adjuvant gemcitabine plus cisplatin vs surveillance and subsequent chemotherapy if needed for patients who underwent nephron-ureterectomy for UTUC.

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

By

Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.

Atezolizumab Has Some Benefits in Urothelial Carcinoma, But OS Not Improved

Atezolizumab Has Some Benefits in Urothelial Carcinoma, But OS Not Improved

By

In the IMvigor 311 trial, researchers sought to determine if atezolizumab improves overall survival for patients with metastatic urothelial carcinoma vs physicians' choice of 3 IV regimens.

Cardiopulmonary Fitness Leads to Better Outcomes in Bladder Cancer Surgery

Cardiopulmonary Fitness Leads to Better Outcomes in Bladder Cancer Surgery

By

A feasibility study involving 60 patients with bladder cancer sought to determine if preoperative vigorous cardiovascular activity would improve postsurgical outcomes.

Age, Race, Sex Affect Survival for Patients With HPV-Associated Cancers

Age, Race, Sex Affect Survival for Patients With HPV-Associated Cancers

By

Using a data sample from the CDC National Program for Cancer Registries, investigators determined how demographic factors — age, race, and sex — impact 5-year survival rates for HPV-associated cancers from initial diagnosis until death.

First-line Pembrolizumab May Be Efficacious for Cisplatin-ineligible Urothelial Cancer

First-line Pembrolizumab May Be Efficacious for Cisplatin-ineligible Urothelial Cancer

By

Approximately 50% of patients with advanced urothelial carcinoma are unable to receive standard first-line cisplatin-based chemotherapy, indicating a need for additional treatment options.

Risk of Bladder Recurrence Reduced With Chemotherapy Flush After Tumor Resection

Risk of Bladder Recurrence Reduced With Chemotherapy Flush After Tumor Resection

By

Flushing the bladder with a chemotherapeutic agent after tumor resection significantly reduced recurrence rates of bladder cancer.

Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress

Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress

By

Patients with urologic cancer should be offered psycho-oncologic support to manage effects of emotional stressors.

Use of Checkpoint Inhibitors in Urothelial Carcinoma

Use of Checkpoint Inhibitors in Urothelial Carcinoma

By

Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

By

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

Metabolic Syndrome More Likely After Platinum-Based Chemotherapy for Testicular Cancer

Metabolic Syndrome More Likely After Platinum-Based Chemotherapy for Testicular Cancer

By

Survivors of testicular cancer are more likely to develop metabolic syndrome after platinum-based chemotherapy.

Nivolumab Approved for Locally Advanced or Metastatic Bladder Cancer

Nivolumab Approved for Locally Advanced or Metastatic Bladder Cancer

By

The US Food and Drug Administration has approved nivolumab (Opdivo) for the treatment of patients with locally advanced or metastatic bladder cancer.

How We Developed a New Protocol for Treatment of Urethral Carcinoma

How We Developed a New Protocol for Treatment of Urethral Carcinoma

Faced with a harsh treatment option, a patient with genitourinary cancer helps create a treatment plan that preserves his self-image.

Nivolumab Monotherapy Active in Recurrent Metastatic Urothelial Carcinoma

By

Single-agent nivolumab induced durable clinical responses with a manageable safety profile in previously treated patients with locally advanced or metastatic urothelial carcinoma.

Insurance Status Linked to Survival in Patients With Testicular Cancer

By

Patients without insurance and those with Medicaid have an increased risk of presenting with advanced testicular cancer and cancer-related death compared with those who have insurance.

Mycobacteria Treatment for Bladder Cancer More Effective With Emulsification in Olive Oil

By

Emulsifying Mycobacterium brumae in olive oil appeared promising for producing a robust immune response in preclinical tests. Recent research has indicated that M brumae is a safer alternative to BCG.

Researchers Estimate Familial Prostate Cancer Risk

Researchers Estimate Familial Prostate Cancer Risk

By

Researchers in Sweden have, for the first time, estimated the risk of developing various types of prostate cancer for men with brothers and/or fathers with the disease.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs